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Abstract
Background: Foxp3 protein plays a critical role in mediating the inflammatory response and can inhibit the
proinflammatory IL-23/IL-17 pathway. However, the molecular interplay of Foxp3 and the IL-23/IL-17 pathway in
patients with chronic hepatitis B (CHB) remains unclear. To this end, we analyzed the expression patterns of Foxp3-
and IL-23/IL-17 pathway-related proinflammatory cytokines in 39 patients with acute-on-chronic liver failure, 71
patients with CHB and 32 healthy controls.
Results: Foxp3 expression was found to be elevated in and mainly expressed by the CD4
+ T cell sub-population of
peripheral blood mononuclear cells and liver tissues of patients with hepatitis B. The intrahepatic expression of
Foxp3 strongly correlated with the copies of HBV DNA and the concentration of surface antigen, HBsAg. IL-23/IL-17
pathway-related proinflammatory cytokines were also found to be significantly increased in patients’ liver tissues, as
compared to healthy controls. Moreover, Foxp3 expression was strikingly correlated with the production of these
cytokines in liver tissues of CHB patients.
Conclusions: The closely-correlated increase of Foxp3 and IL-23/IL-17 pathway activity in HBV-infected livers
suggests that the proinflammatory IL-23/IL-17 pathway had not been effectively suppressed by the host immune
machinery, such as Treg (Foxp3) cells. Constitutive activation of the IL-23/17 pathway, thus, may support the
chronic hepatitis B state.
Keywords: Treg Foxp3, Th17, IL-23, IL-17, Hepatitis B
Background
Hepatitis B virus (HBV) is a noncytopathic, hepatotropic
DNA virus that is capable of inducing acute and chronic
necroinflammatory liver injury [1]. Outcome of patients
infected with HBV is closely associated with the extent
of host immune response [2]. Moderate immune
responses will mediate the clearance of HBV infection,
while excessive responses will induce liver injury and
low level responses will allow HBV residence. Unfortu-
nately, patients with chronic hepatitis B (CHB) often
exhibit impaired HBV-specific T cell responses [3]. The
exact mechanisms of the immune system that fail in
CHB infections remain unclear and, thus, remain a hin-
drance to the development of effective therapies.
Many mechanisms have been hypothesized to explain
the inadequate immune responses that facilitate chronic
HBV infection. The most recent has focused on the dys-
function of regulatory T (Treg) cells. Treg cells are char-
acterized by their cell-specific expression of Forkhead
box P3 (Foxp3) [4], a transcription factor that contri-
butes to autoimmune functions. Studies have demon-
strated that Foxp3
+ Treg cells can inhibit activation,
proliferation and effector functions of several kinds of
other immune cells, including CD4
+ and CD8
+ Tc e l l s ,
natural killer (NK) and NKT cells, B cells and dendritic
cells (DC). As such, Foxp3
+ Treg cells are widely con-
sidered to be the principal mediator of dominant self-
tolerance and immune homeostasis and to contribute to
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and allergy [5]. In HBV patients, Foxp3
+ Treg cells have
been associated with the incidence and extent of liver
damage [6-10].
Chronic inflammation of the liver, known as hepatitis,
is most commonly caused by infection with HBV. Many
other inflammation-related diseases, such as multiple
sclerosis, psoriasis, rheumatoid arthritis, inflammatory
bowel disease, and asthma [5,11,12], have been charac-
terized as having significant dysfunctions in the interleu-
kin (IL)-23/IL-17 signaling pathway. Interestingly, IL-17
has been associated with the pathogenesis of chronic
hepatitis B in humans [13,14]; however, the relationship
between Foxp3
+ Tregs and the IL-23/IL-17 pathway (via
Th17 cells) has not yet been investigated in HBV
infected individuals.
This study was designed to elucidate the Foxp3-
mediated activity of the IL-23/IL-17 signaling pathway
in HBV-infected patients. We found that both Foxp3
and IL-23/IL-17 pathway-related cytokines were sharply
increased in patients with CHB, as compared to healthy
controls. We also determined that Foxp3 gene expres-
sion was positively associated with the presence of IL-
23/IL-17 pathway cytokines at sites of inflammation.
These findings suggest that both Foxp3 and the IL-23/
IL-17 pathway are involved in inflammatory response to
hepatitis B infection, and may interact with one another
in CHB patients.
Methods
Patients and samples
One hundred and ten HBV-infected patients including
thirty-nine acute-on-chronic liver failure (ACLF) and
seventy-one chronic hepatitis B patients (CHB) were
recruited for the study and enrolled when written,
informed consent was obtained. Each patient was hospi-
talized and clinically followed upon release in the
Department of Infectious Diseases, Southwest Hospital,
Third Military Medical University. The study period
lasted from December 2007 to January 2010. All indivi-
duals were confirmed as HBV positive, and negative for
C and D types (HCV, HDV) and human immunodefi-
ciency virus. Clinical records and self-reporting indi-
c a t e dt h a tn oa n t i - H B Va g e n t so rs t e r o i d sw e r e
administered six months before study sampling.
Twenty-four healthy blood donors (healthy controls,
HC) and eight healthy liver tissue samples from liver
transplantation patients were also selected. The study
was approved by the ethics committee of the Third
Military Medical University, Chongqing, China.
Informed consent was obtained from all patients. The
clinical characteristics of our patient cohort and healthy
controls are shown in Table 1.
Flow cytometry (FCM) analysis
The following antibodies were used: AF750-conjugated
anti-CD3 (eBioscience, San Diego, CA, USA), PerCP-
C y 5 . 5 c o n j u g a t e da n t i - C D 4 ,a n dA P C - c o n j u g a t e da n t i -
Foxp3. Peripheral blood mononuclear cells (PBMC) were
obtained by Ficoll gradient. Cells were then stained to
detect relevant surface markers, fixed, permeabilized with
Cytofix/Cytoperm solution (BD Biosciences), and stained
with anti- Foxp3. Detection was carried out on a FAC-
SAria cell sorter (BD Biosciences), and data were ana-
lyzed by FlowJo v. 6.1 (TreeStar, Inc., Ashland, OR, USA).
Total RNA isolation and quantitative PCR
PBMC and liver tissues were dissolved in TRIzol (Invi-
trogen, Carlsbad, CA, USA) for total RNA extraction.
RT-PCR was carried out on the RNA product by using
the PrimeScript™ RT reagents kit (TaKaRa, Shiga,
Japan), following the manufacturer’s directions. Quanti-
tative real-time (q)PCR was performed using the SYBR
®
Premix Ex Taq™ (TaKaRa). Gene-specific primers for
human IL-17, IL-23, Foxp3, TNF-a and IL-8 were
designed as shown in Table 2. Fluorescence signals were
measured after 40 PCR cycles, and all samples were nor-
malized to GAPDH housekeeping gene levels. All sam-
ples were run in duplicate.
Immunohistochemistry analysis
Liver tissues were embedded in paraffin using the stan-
dard protocol. Immunohistochemistry for human Foxp3
was performed as previously described, with minor modi-
fications [9]. Briefly, masked antigens were uncovered by
microwaving for 20 min in citrate buffer, pH 6.0. After
cooling at room temperature, non-specific binding was
blocked by exposure to 5% bovine serum albumin (BSA)
in phosphate-buffered saline (PBS) for 30 min. Incuba-
tion with primary antibodies for Foxp3 (Abcam, Cam-
bridge, MA, USA) was carried out for 48 h at 4°C in a
humidified chamber before the slides were incubated
with secondary, biotin-conjugated antibody, followed by
sequential incubation with horseradish peroxidase-strep-
tavidin and the peroxidase substrate 3’-diaminobenzidine.
Samples were then counterstained with hematoxylin.
For the double staining of anti- Foxp3 plus anti-CD4
and anti- Foxp3 plus anti-CD8, the first antibody
(diluted 1:200) was applied for 48 h at 4°C in a humidi-
fied chamber. The second antibody, anti-human CD4
and CD8 (diluted 1:100 in PBS containing 5% BSA;
eBioscience), was then applied for overnight at 4°C.
CY3-labeled anti-goat IgG (diluted 1:500 in PBS) and
Dylight488-labeled anti-mouse IgG (diluted 1:200)
(Zhongshan Goldenbridge Biotechnology, Beijing,
China) were applied for 60 min at 37°C. Nuclear coun-
terstaining was performed by incubating stained samples
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Invitrogen) for 5 min. Normal mouse or goat IgG was
used as a negative control. Images were obtained by the
digital confocal laser scanning system MRC-600 (Bio-
Rad, Hercules, CA, USA).
Western blot
Total protein of liver tissue was extracted using T-PER
®
Tissue Protein Extraction Reagent (Pierce, Rockford, IL,
USA) and quantified with BCA™ Protein Assay (Pierce).
The proteins were separated on a 16% SDS-PAGE and
transferred onto polyvinylidene fluoride (PVDF) mem-
branes for immunoblotting. The membranes were incu-
b a t e dw i t hg o a ta n t i - h u m a nI L - 1 7( R & DS y s t e m s ,
Wiesbaden, Germany), mouse anti-human IL-23p19 (Bio-
Legend, San Diego, CA, USA) and mouse anti-human
Foxp3 (eBioscience, San Diego, CA, USA) for 1 h at room
temperature, respectively. After incubation with peroxi-
dase-conjugated rabbit anti-goat IgG, or rat anti-mouse
IgG for 1 h at room temperature, specific protein bands
on the membranes were visualized by the enhanced che-
miluminescence method (Amersham, Piscataway, NJ,
USA), according to the manufacturer’si n s t r u c t i o n s .
Virological assessment
The virological assay was performed as previously
described [15].
Statistical analysis
Comparisons between various groups were performed
using the Mann-Whitney U test. Results are expressed
as the mean ± standard deviation (SD), unless otherwise
noted. Correlations between variables were evaluated
using the Spearman’s rank correlation. For all tests, 2-
sided P < 0.05 was considered significant.
Results
Foxp3 expression is significantly high in peripheral blood
of CHB patients
Tregs with transcription factor Foxp3 play an pivotal
role in controlling immune response mediated inflam-
mation [16]. Several reports have shown evidence that
Treg cells are involved in hepatitis B pathogenesis
[6-10]. To further explore the role of Foxp3 in patients
with hepatitis B, we collected the peripheral blood from
34 CHB patients and 30 ACLF patients, and then evalu-
ated the expression of Foxp3 as detected by qPCR and
FCM assays. As shown in Figure 1A, the expression of
Foxp3 mRNA was found to be significantly increased in
PBMC of CHB and ACLF patients, as compared with
healthy controls. FCM assays indicated that the Foxp3
+
T cell portion of CD4
+ T cells were markedly up-regu-
l a t e di nH B V - i n f e c t e dp a t i e nts; the ACLF patients had
the most Foxp3
+ T cells (Figure 1B and 1C).
Foxp3 is significantly augmented in liver tissue of
patients infected with HBV
To further value the role of Foxp3 in patients with
hepatitis B, we detected the expression level of Foxp3 in
liver tissue from patients infected by HBV by using
qPCR and immunohistochemistry techniques. Concor-
dant with the data from Xu et al. [9] and Janssen’s
group [8], Foxp3 was found to be mainly localized to
cells near the hepatic portal tract, and Foxp3 expression
was significantly higher in HBV patients than in healthy
controls (Figure 2A and 2B). We further investigated
the distribution patterns of Foxp3 expression in HBV-
infected liver tissue by immunofluorescent confocal
microscopy. Results revealed that Foxp3 in HBV-
infected liver tissues was predominantly present in CD4
+ T cells, and not in CD8
+ T cells (Figure 2C and 2D).
Increased Foxp3 expression is positively correlated with
HBV persistence in host liver
In order to evaluate the relationship between Foxp3
expression and clinical symptom of patients with CHB,
we analyzed the Foxp3 expression in liver tissue and
plasma HBV DNA copies, hepatitis B surface antigen
(HBsAg) concentration, and serum alanine
Table 1 Clinical characteristics of the study’s subjects
Subjects Cases Sex (F/M) Age in years (mean, range) ALT in U/L (mean, range) HBsAg
+ HBeAg
+ HBcAb
+ HBV DNA
+
HC 32 4/14 27 (17-42) < 40 0 0 0 0
CHB 71 8/63 32 (18-42) 136 (53-326) 71 71 71 71
ACLF 39 3/36 28 (20-39) 206.34 (92-1675) 39 9/39 39 39
Table 2 Primer design for detection of target genes
Genes Forward primer Reverse primer
Foxp3 5’-AAGGAAAGGAGGATGGACG-
3’
5’-CAGGCAAGACAGTGGAAACC-
3’
IL-23 5’-GCTTCAAAATCCTTCGCAG-3’ 5’-TATCTGAGTGCCATCCTTGAG-
3’
IL-17 5’-TCAACCCGATTGTCCACCAT-3’ 5’-
GAGTTTAGTCCGAAATGAGGCTG-
3’
IL-8 5’-
TTCTAGGACAAGAGCCAGGAAG-
3’
5’-
GGGTGGAAAGGTTTGGAGTATG-
3’
TNF-a 5’-
ATGAGCACTGAAAGCATGATCC-
3’
5’-
GAGGGCTGATTAGAGAGAGGTC-
3’
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was significant association between Foxp3 expression
and HBV DNA copies or HBsAg concentration, but not
ALT (Figure 3). These results suggested that Foxp3 was
involved in the persistent presence of HBV in CHB
patients, but not directly involved in liver injury.
Expression of IL-23/IL-17 pathway proinflammatory
cytokines was significantly high in HBV-infected liver
tissues
Inflammatory responses are significant features of hepa-
titis B pathogenesis. It has been reported that the IL-23/
IL-17 pathway plays a critical role in inflammatory
diseases [17,18]. Moreover, Foxp3 is closely related to
the IL-23/IL-17 signaling pathway [19]. In order to
further elucidate the role of Foxp3 in patients with
CHB, we detected the expression of IL-23/IL-17 path-
way-related cytokines in CHB liver samples. As shown
in Figure 4A, the mRNA expression of IL-23, IL-17,
TNF-a, and IL-8 was significantly higher in these
patients liver tissues than in healthy controls. We then
investigated whether the protein expression of the key
genes, Foxp3, IL-23 and IL-17 genes, was also enhanced
in CHB liver tissues by Western-blot assay. Results
showed that the protein expression of these three genes
in liver tissue of CHB patients was significantly elevated
Figure 1 Foxp3 expression is significantly higher in peripheral blood of patients with CHB. PBMC from healthy controls and patients with
CHB or ACLF were used to detect the expression levels of Foxp3 by qPCR (A) and flow cytometry (B and C). (A) Relative mRNA expression of
Foxp3 in PBMC. (B) Pooled data indicating the percentages of Foxp3
+ cells in total CD4
+ T cells. (C) Representative dotplots of Foxp3
+ cells in
CD4
+ T cells. The values in the quadrants indicate the percentage of each CD4
+ T cell subset. Error bars indicate SD; *, P < 0.05; **, P < 0.01; ***,
P < 0.001.
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Page 4 of 9Figure 2 Foxp3 is significantly augmented in liver tissue of patients infected with HBV. Liver biopsy samples from healthy controls and
patients with CHB or ACLF were used for the detection of Foxp3 mRNA by qPCR (A) and visualization of Foxp3 by immunohistochemistry (B)
and laser scanning confocal microscopy (C, D). (A) Relative mRNA expression of Foxp3 in liver tissues. Error bars indicate SD; *, P < 0.05; **, P <
0.01. (B) In situ expression of Foxp3 in liver tissues. The Foxp3 expressing cells are stained brown. Representative results are shown from three
independent experiments (100 × magnification). (C, D) Co-localization of Foxp3 with CD4 or CD8 in liver tissues from CHB patients. Anti- Foxp3
(red); anti- CD4 (green); anti- CD8 (green); and DAPI (blue). Representative results are shown from three independent experiments (200 ×
magnification). The right panels represent the enlarged portion of the indicated (white hatched box) area in the left panels.
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Treg cells and Th17 cells might play important roles
simultaneously in CHB pathogenesis.
Foxp3 expression is positively correlated with presence of
IL-23/IL-17 pathway-related cytokines in liver tissue from
CHB patients
Foxp3 is a potent mediator of dominant self-tolerance
and immune homeostasis. Nistala et al. [20] demon-
strated an inverse relationship between IL-17
+ Tc e l l s
and Foxp3
+ Treg cells in joint tissues of children suffer-
ing from juvenile arthritis. The fact that Foxp3 and IL-
23/IL-17 pathway cytokines were both significantly
increased in patients with CHB led us to examine the
relationship between these molecules in liver tissues
infected with HBV. We found that Foxp3 was signifi-
cantly correlated with the presence of IL-23 and IL-17
at sites of inflammation (Figure 5).
Discussion
Immune-mediated liver injury is the key feature of hepa-
titis B pathogenesis. Recently, much attention has been
paid to the importance of Treg cells in chronic HBV
infection [21]. In the study described herein, we investi-
gated the expression levels of Foxp3 (the cell-specific
transcription factor of Treg cells) and IL-23/IL-17 path-
way-related cytokines in HBV-infected liver tissue. We
found that Foxp3 and IL-23/IL-17 pathway-related cyto-
kines were significantly higher at sites of inflammation.
Moreover, the expression of Foxp3 was closely corre-
lated with the presence of IL-23/IL-17 pathway-related
cytokines.
The inflammatory response is necessary to clearance
of pathogenic agents, but a fine balance must be main-
tained so that chronic inflammation does not damage
healthy tissues. Treg cells that express Foxp3 play a key
role in regulating this delicate equilibrium [22]. Several
studies of HBV infection have found that Treg cells are
functionally involved in the hepatic immunological
responses [6-10]. Likewise, we also observed Foxp3
expression in CD4
+ T cells, and not in CD8
+ Tc e l l s .
Moreover, the expression of Foxp3 was significantly
increased and in liver tissue of CHB patients. Moreover
the mRNA level of Foxp3 at sites of hepatic inflamma-
tion was closely correlated with levels of HBV DNA
copies and HBsAg. These results indicated that Foxp3
expression was likely to support established residence of
HBV.
Recently, clinical investigations have shown that the
IL-23/IL-17 signaling pathway contributes to the inflam-
matory reaction of Crohn’s disease, psoriasis and sys-
temic lupus erythematosus [18,23,24]. IL-17 is known as
the immune-modulatory factor of Th17 cells, while IL-
23 functions to elicit the differentiation and mediate the
function of Th17 cells [25]. Several groups have
reported that the IL-17 pathway was involved in human
liver disease [13,14,26,27]. Our results evidenced that
the activity of the IL-23/IL-17 pathway was significantly
elevated in liver tissues of patients infected by hepatitis
B virus, as compared to that in healthy controls. These
results indicated that the IL-23/IL-17 pathway, rather
than IL-17 alone, is involved in the pathological process
of hepatitis B infection.
T h 1 7c e l l sa n dT r e gc e l l sb o t ha r i s ef r o mt h en a i v e
CD4
+ T cell population and share reciprocal develop-
ment pathways. But, they have opposite immunomodu-
latory effects, and the balance between them controls
inflammation and autoimmune diseases [28]. Many stu-
dies have identified an imbalance in Th17 cells and
Treg cells that occurs in conjunction with disease
[6,29-31]. In the present study, we found that expression
of Foxp3 and IL-23/IL-17 pathway-related cytokines
Figure 3 Increased Foxp3 expressions is positively correlated with HBV persistence in host liver. Liver biopsy samples from 38 CHB
patients were used for the detection of Foxp3 mRNA by qPCR. Sera and plasma samples from CHB patients were measured for ALT level, log10
HBsAg (IU/ml), or log10 HBV loads (copies/ml). The relationships between Foxp3 and clinical symptoms of these patients were analyzed. P < 0.05
was considered significant.
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patients. We also found that Foxp3 expression was sig-
nificantly correlated with levels of IL-23/IL-17 pathway-
related cytokines in the livers of these CHB patients
(Figure 5). Several studies have demonstrated that the
development of Th17 cells and Treg cells may be inter-
related, as they are both dependent on TGF-b [32]. Yet,
they appear to be reciprocally influenced by various
cytokines, such as IL-6, IL-1, as well as IL-2 and the
vitamin A metabolite all-trans-retinoic acid [33-35].
TGF-b is central to the development and function of
Th17 and Treg cells. On one hand, TGF-b induces the
expression of FoxP3 [36]; on the other hand, TGF-b has
been shown to be absolutely required for Th17 differen-
tiation in a serum-free system using cord blood-derived
CD4
+ T cells [37]. A recent study also showed that
Tregs themselves may differentiate into IL-17-producing
cells, particularly when exposed to exogenous IL-1b,I L -
23 or IL-21 [38,39]. In psoriasis patients, Zhang et al.
found that Th17 cells were positively correlated with the
presence of Treg cells, both in the circulation and in
skin tissue lesions [40]. Based on these data, we propose
that Tregs may act to promote the pro-inflammatory
cytokines, such as IL-17 and IL-23, at certain time
points during the course of HBV infection. Considering
that the inflammatory response is crucial for clearance
of pathogenic microorganisms, it is reasonable that the
occurrence of pro-inflammatory immune cells, such as
Th17, will be accompanied by inhibitory Tregs cells. In
this way, the significant correlation between Treg cells
and Th17 cells in the liver of CHB patients is fitting.
Conclusions
We have demonstrated that Foxp3 and IL-23/IL-17 path-
way-related cytokines were both highly expressed in
inflamed liver tissues infected by hepatitis B virus. More-
over, the expression of Foxp3 was significantly correlated
with that of IL-23/IL-17 pathway-related cytokine genes in
the infected liver. These findings support the hypothesis
that proinflammatory Th17 (IL-23/IL-17) cells in HBV-
infected liver is accompanied by host inflammation-
Figure 4 HBV-infected liver tissues express higher levels of IL-
23/IL-17 pathway-related cytokines than non-infected tissues.
Liver biopsy samples from healthy controls and CHB patients were
used to detect mRNA level for IL-23, IL-17, TNF-a and IL-8 by qPCR
(A), and protein expression level of Foxp3, IL-23 and IL-17 by
Western-blot assay (B). Error bars indicate SD; **, P < 0.01 vs HC; ***,
P < 0.001 vs HC.
Figure 5 Foxp3 expression is positively correlated with IL-23/
IL-17 pathway in host liver. Liver biopsy samples from 38 CHB
patients were used to detect mRNA for Foxp3, IL-23, IL-17, TNF-a
and IL-8 by qPCR, and then the relationship between Foxp3 and IL-
23, IL-17, TNF-a or IL-8 was analyzed. P < 0.05 was considered
significant.
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to maintain balance between promotion and inhibition of
the immune response. Our results also suggested that the
activity of the proinflammatory IL-23/IL-17 signaling path-
way is not been efficiently controlled by the host inhibitory
machinery, in this case the Treg (Foxp3) cells; the consti-
tutive activation of the IL-23/IL-17 signaling pathway may
partially explain the HBV persistence that occurs in the
chronic hepatitis B state. Future studies will address the
precise in vivo mechanism of the reciprocal regulation
between Foxp3 and the IL-23/IL-17 pathway, and will con-
tribute to development of effective therapies to clear HBV
from CHB patients.
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